Open AccessCombined treatment with terbutaline and aminophylline inhibits experimental amyloidosis in mice
Author(s) -
Brandwein Sydney R.,
Sipe Jean D.,
Cohen Alan S.
Publication year - 1994
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.1780371208
Subject(s) - aminophylline , terbutaline , amyloidosis , phosphodiesterase inhibitor , medicine , colchicine , theophylline , cyclic adenosine monophosphate , endocrinology , pharmacology , stimulation , salbutamol , aa amyloidosis , amyloid (mycology) , chemistry , pathology , receptor , asthma , familial mediterranean fever , disease
Objective . To investigate the effects of drugs known to elevate adenosine 3':5'‐cyclic monophosphate (cAMP) on experimental amyloidosis. Methods . A β 2 ‐agonist, terbutaline, and a phosphodiesterase inhibitor, aminophylline, were administered in combination in a mouse model of amyloidosis induced by inflammatory stimulation with silver nitrate. Amyloidosis was quantitated by radioimmunoassay for splenic amyloid A (AA) protein. Results . At the doses selected, aminophylline/ terbutaline inhibited splenic amyloid deposition more potently than did colchicine, a known inhibitor of amyloidosis. Conclusion . Drugs known to elevate cAMP inhibit experimental mouse AA amyloidosis.